J&J lines up its 4-in-1 HIV pill for FDA be­hind ri­vals from Gilead, GSK

A cou­ple of months af­ter post­ing pos­i­tive late-stage da­ta for its quadru­plet-in-one-pill for quelling HIV, J&J says it’s filed a mar­ket­ing ap­pli­ca­tion with the FDA ahead of a planned mar­ket­ing cam­paign.

Cock­tail ther­a­pies have proven high­ly ef­fec­tive at keep­ing HIV at bay, but the big play­ers in the mar­ket — like Gilead, GSK and J&J — have all been hus­tling along to prove that their com­bos can do the job while promis­ing to im­prove ad­her­ence to drug reg­i­mens and height­en their con­sis­ten­cy.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN